Janux Therapeutics

Janux today reported first quarter 2026 financial results and recent business highlights. During the quarter, we continued to advance our prostate cancer franchise, with JANX007 enrolling in its Phase 1b trial in metastatic castration-resistant prostate cancer, including in combination with darolutamide, and initiated clinical evaluation of JANX014, a double-masked PSMA-TRACTr candidate. We also continued enrollment in the Phase 1 study of JANX011, our CD19-targeted ARM program in healthy volunteers for potential use in autoimmune disease, advanced JANX013 toward planned clinical initiation in the second half of 2026, and achieved development candidate nomination under our Bristol Myers Squibb collaboration. We look forward to continued execution across our TRACTr, TRACIr, and ARM platforms as we work to advance a broad pipeline of novel immunotherapies. Read the press release for more: https://lnkd.in/gue69DuG #JANX

Janux announced today that the first patient has been dosed in a Phase 1 clinical trial of JANX014, a PSMA-directed, double-masked T cell engager designed with our tumor-activated technology platform for patients with metastatic castration-resistant prostate cancer (mCRPC). Janux is building a portfolio of tumor-activated PSMA therapies intended to address multiple treatment settings and mechanisms of immune engagement in prostate cancer. JANX007 remains our lead prostate cancer program and primary development priority, and insights from JANX007 and JANX008 have helped inform continued platform development. JANX014 represents an exploratory extension of this strategy and will evaluate a distinct molecular design as Janux continues advancing complementary PSMA-directed approaches, including JANX013, our CD28 co-stimulatory PSMA-TRACIr program planned to enter the clinic in the second half of 2026. The Phase 1 study will assess the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary efficacy of JANX014 in adults with mCRPC. Read the press release for more: https://lnkd.in/gZrjiX9Z #JANX

Janux Therapeutics announced the nomination of a development candidate under its collaboration with Bristol Myers Squibb, triggering a $35 million milestone payment to Janux. The achievement reflects the strength of our tumor-activated platforms and our ability to advance differentiated therapeutics through strategic collaboration. Read the press release for more: https://lnkd.in/gruwDU49    #JANX #TCellEngagers

Today we reported our fourth quarter and full year 2025 financial results and business highlights. Janux continues to advance its broad pipeline of novel immunotherapies built on our proprietary TRACTr, TRACIr, and ARM platforms. Enrollment is ongoing across our TRACTr programs, including JANX007 in metastatic castration-resistant prostate cancer, with continued dose optimization in taxane-naïve patients, and JANX008 in defined solid tumor settings with expansion cohorts in progress. We also initiated our Phase 1 study of JANX011, our CD19-ARM program, in healthy volunteers. In addition, we entered a collaboration and exclusive worldwide license agreement with Bristol Myers Squibb to develop a novel tumor-activated therapeutic for solid tumors, further supporting the advancement of our platform. With three wholly owned programs now in clinical development and a growing pipeline behind them, we are positioned to translate our tumor-activated and adaptive immune response platform into differentiated immunotherapies for patients. Read the press release for more: https://lnkd.in/gPpUJKkr

Janux announced today that the first participant has been dosed in the Phase 1 study of JANX011, a CD19-targeted bispecific engineered using our Adaptive Immune Response Modulator (ARM) platform. The ARM platform is designed to deliver sustained target cell depletion by harnessing a controlled, adaptive immune response with transient T-cell expansion, followed by contraction, rather than continuous immune engagement. In preclinical studies, JANX011 demonstrated deep and durable B-cell depletion in blood and tissue, prolonged memory B-cell reset, and no evidence of cytokine release syndrome. The Phase 1 study in healthy adult volunteers will evaluate safety, pharmacokinetics, and pharmacodynamics to inform future development in autoimmune diseases. We’re proud of the team for reaching this important milestone and look forward to advancing the program. Read the press release for more: https://lnkd.in/gxtASP6F #JanuxTherapeutics #Immunology #AutoimmuneDisease #ClinicalTrials

We’re pleased to welcome Dr. William Go as Chief Medical Officer of Janux Therapeutics. Will brings more than 20 years of hematology and oncology experience, including leadership of CAR T-cell programs from early clinical development through pivotal trials, regulatory approval, and launch. Most notably, he led the study that supported FDA and EMA approvals of YESCARTA®, the first CAR T-cell therapy approved for large B-cell lymphoma. He also led the development of CAR T-cell therapies for solid tumors, initiating three Phase 1 clinical trials across multiple indications. He joins Janux at an important stage as we continue to advance our tumor-activated immunotherapy pipeline and scale our clinical and regulatory efforts. We also want to thank Zach for his contributions to Janux. He played an important role during a formative period for the Company, and we wish him well in what comes next. Read the release here: https://lnkd.in/gY6-Yaj4 #JANX #TRACTr #TRACIr #TCellEngagers #cancer #oncology #immunotherapy

Janux Therapeutics has entered into a collaboration and exclusive worldwide license agreement with Bristol Myers Squibb to develop a novel tumor-activated therapeutic for solid tumors. This collaboration reflects the strength of our tumor-activated platforms and a shared commitment to advancing next-generation immunotherapies for patients. Read the press release for more: https://lnkd.in/g6PqSaCC    #JANX #TCellEngagers #cancer #oncology

Janux Therapeutics today provided a program update on its ongoing Phase 1 clinical study evaluating JANX008, an EGFR targeted TRACTr, in multiple solid tumor indications. The Phase 1a dose escalation portion of the study has been completed, and expansion cohorts have been initiated to support continued dose optimization and further evaluation across selected solid tumor settings. Janux expects to share additional updates on JANX008 as the study progresses and data continue to mature. Read the full announcement here: https://lnkd.in/gpcQMi3h #JANX #TCellEngagers #cancer #oncology #immunotherapy #immunomodulator #immunooncology #clinicaltrial

Today we announced positive updated interim data from the ongoing Phase 1 clinical trial evaluating JANX007 in patients with mCRPC. These interim data showed durable responses with a manageable safety profile in heavily pretreated patients, and preliminary findings in the taxane naive Phase 1b expansion showed rapid and deep PSA reductions with an emerging CRS profile that supports current development plans. Initial results also support evaluation of a Q2W dosing schedule that may provide convenience benefits for patients. We will review the results during a virtual investor event today at 4:30 pm ET. Read the full release and register here: https://lnkd.in/gWpXDhZQ #JANX #TCellEngagers #cancer #oncology #immunotherapy #immunomodulator #immunooncology #clinicaltrial #mCRPC #prostatecancer

We will be hosting a virtual event on Monday, December 1st at 4:30pm ET to discuss updated Phase 1a and Phase 1b clinical data for JANX007 in #mCRPC. A live analyst Q&A session will follow the formal presentation. For details on how to register for the event, see the press release: https://lnkd.in/gyjPEBR2 #JANX #TCellEngagers #cancer #oncology #immunotherapy #immunomodulator #immunooncology #clinicaltrial #mCRPC #prostatecancer